Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

Clinical and Vaccine Immunology , Volume 18 (9): 1586 – Sep 1, 2011

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

Loading next page...
 
/lp/american-society-for-microbiology/adeno-associated-virus-antibody-profiles-in-newborns-children-and-sQw1FkwAM5

References (20)

Publisher
American Society For Microbiology
Copyright
Copyright © 2011 by the American Society For Microbiology.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.05107-11
Publisher site
See Article on Publisher Site

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Sep 1, 2011

There are no references for this article.